With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...